Pharmacokinetics, Excretion, and Mass Balance of $[^{14}C]$-Rezafungin Following Intravenous (IV) Administration in Healthy Adults

V. Ong$^1$, S. Flanagan$^1$, T. Sandison$^1$, S. Wills$^2$

$^1$Cidara Therapeutics, San Diego, CA; $^2$Covance Laboratories, Madison, WI

**INTRODUCTION**
Rezafungin is a once-weekly novel echinocandin antifungal currently in ongoing Phase III clinical development (ReSTORE trial [NCT03667690] in treatment of candidemia and invasive candidiasis and ReSPECT trial [NCT04385599] in prophylaxis against invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp.

Rezafungin’s distinctive pharmacokinetics (PK) allow for once-weekly dosing and high, front-loaded drug exposures.

Rezafungin has demonstrated extensive distribution and penetration to sites of infection with greater antifungal efficacy in vivo compared with current echinocandins[1].

Nonclinical ADME studies[2] show rezafungin is primarily excreted unchanged in feces, with urine as a minor route. This study was conducted to characterize the PK, excretion, and PK of $[^{14}C]$-rezafungin in human subjects to produce inter-subject time point pools. Urine and feces were collected over 60 days; subjects were initially confined in the clinical research unit (CRU) for 17 days postdose and returned for two follow-up visits (days 29 and 60). Committed whole blood, plasma, urine, and fecal samples were analyzed by liquid scintillation counting. Recovery periods of subjects were away from the CRU, recovery of radioactivity was estimated by linear interpolation. Rezafungin concentration was measured by LC-MS/MS.

Metabolite Profiling. Plasma samples were pooled across subjects to produce inter-subject time point pools. Urine and fecal samples were pooled by subject across various time points up through 408 and 672 hours postdose, respectively. Selected plasma, urine, and fecal samples were profiled for rezafungin and metabolites by LC with radiochemical and high-resolution mass spectrometry detection; metabolites were identified by chromatography with known standards and/or by LC-MS/MS structure elucidation.

**RESULTS**
Rezafungin exhibited a long plasma half-life. Mean blood-to-plasma concentration ratios ranged from 0.860 to 1.02 through the last collection time point (day 60), which indicated low association of radioactivity with blood cells.

Fig 1. Mean Concentration-Time Profiles for Whole Blood/Plasma Radioactivity and Plasma Rezafungin

Linear

Semi-log

Table 1. Mean (SD) PK Parameters for Rezafungin, Plasma Total Radioactivity, and Whole Blood Total Radioactivity

**REFERENCES**
2. Ong V, et al. Absorption, Distribution, and Excretion of $[^{14}C]$Rezafungin after Single-Dose Intravenous (IV) Administration in Rats and Monkeys" 29th European Congress of Clinical Microbiology & Infectious Diseases, 2019

**CONCLUSIONS**
Results from this human excretion balance, metabolism, and PK study are consistent with nonclinical results, which showed fecal excretion as the major route of elimination of $[^{14}C]$-rezafungin. Overall, rezafungin underwent minimal metabolism and slow elimination after IV administration.

**ACKNOWLEDGMENTS**
Editorial assistance provided by T. Chung (Scribant Medical) with funding from Cidara.

**RESULTS (cont’d)**
Rezafungin was mainly excreted unchanged in feces. Cumulative recovery of radioactivity from excreta collected through the first 17 days was 52.3% (37.8% in feces, 14.5% in urine) indicating the slow elimination of rezafungin.

Fig 2. Recovery of Radioactivity – first 17 Days Postdose (%)

Based on linear interpolation, by day 60, overall recovery of the administered dose was estimated to be 88.3% (65.6% in feces, 22.7% in urine).

Fig 3. Recovery of Radioactivity – by Day 60 Postdose (%)

CONCLUSIONS (cont’d)
As similarly found in animals, rezafungin was the predominant compound measured in plasma and feces across all collected time points. In the urine, low level, inactive, oxidative metabolites were identified as 2-, 3-, 4-hydroxypentyl rezafungin, and despentyl-rezafungin. Rezafungin accounts for ~77% of total plasma radioactivity AUC, and metabolites accounted for less than 10% of the total plasma radioactivity AUC exposure.

Fig 4. Radioactivity Concentration (semi-log) -Time Profile in Plasma

**REFERENCES**
2. Ong V, et al. Absorption, Distribution, and Excretion of $[^{14}C]$Rezafungin after Single-Dose Intravenous (IV) Administration in Rats and Monkeys" 29th European Congress of Clinical Microbiology & Infectious Diseases, 2019

**ACKNOWLEDGMENTS**
Editorial assistance provided by T. Chung (Scribant Medical) with funding from Cidara.

**RESULTS (cont’d)**
As similarly found in animals, rezafungin was the predominant compound measured in plasma and feces across all collected time points. In the urine, low level, inactive, oxidative metabolites were identified as 2-, 3-, 4-hydroxypentyl rezafungin, and despentyl-rezafungin. Rezafungin accounts for ~77% of total plasma radioactivity AUC, and metabolites accounted for less than 10% of the total plasma radioactivity AUC exposure.

Fig 4. Radioactivity Concentration (semi-log) -Time Profile in Plasma

**CONCLUSIONS**
Results from this human excretion balance, metabolism, and PK study are consistent with nonclinical results, which showed fecal excretion as the major route of elimination of $[^{14}C]$-rezafungin. Overall, rezafungin underwent minimal metabolism and slow elimination after IV administration.

**REFERENCES**
2. Ong V, et al. Absorption, Distribution, and Excretion of $[^{14}C]$Rezafungin after Single-Dose Intravenous (IV) Administration in Rats and Monkeys" 29th European Congress of Clinical Microbiology & Infectious Diseases, 2019

**ACKNOWLEDGMENTS**
Editorial assistance provided by T. Chung (Scribant Medical) with funding from Cidara.

**RESULTS (cont’d)**
As similarly found in animals, rezafungin was the predominant compound measured in plasma and feces across all collected time points. In the urine, low level, inactive, oxidative metabolites were identified as 2-, 3-, 4-hydroxypentyl rezafungin, and despentyl-rezafungin. Rezafungin accounts for ~77% of total plasma radioactivity AUC, and metabolites accounted for less than 10% of the total plasma radioactivity AUC exposure.

Fig 4. Radioactivity Concentration (semi-log) -Time Profile in Plasma

**CONCLUSIONS**
Results from this human excretion balance, metabolism, and PK study are consistent with nonclinical results, which showed fecal excretion as the major route of elimination of $[^{14}C]$-rezafungin. Overall, rezafungin underwent minimal metabolism and slow elimination after IV administration.

**REFERENCES**
2. Ong V, et al. Absorption, Distribution, and Excretion of $[^{14}C]$Rezafungin after Single-Dose Intravenous (IV) Administration in Rats and Monkeys" 29th European Congress of Clinical Microbiology & Infectious Diseases, 2019

**ACKNOWLEDGMENTS**
Editorial assistance provided by T. Chung (Scribant Medical) with funding from Cidara.